SHINGRIX Shingles Vaccine Summary
Overview
SHINGRIX is a recombinant zoster vaccine designed to prevent shingles and its complications, such as postherpetic neuralgia (PHN). It contains a gE antigen from genetically engineered Chinese Hamster Ovary cells and an AS01B adjuvant, including components like QS21, MPL, and polysorbate 80.
Efficacy
SHINGRIX reduces the risk of shingles and PHN. Clinical data indicate it prevents one case of PHN per 356 fully vaccinated individuals. Efficacy wanes over time:
- Year 1: 67%
- Year 2: 50%
- Year 8: 27%
- Year 10: 15%
Warnings and Precautions
- Guillain-Barré Syndrome (GBS): Postmarketing surveillance noted increased GBS cases within 42 days post-vaccination, prompting a Black Box Warning.
- Syncope: Fainting may occur, requiring emergency measures to prevent injury.
- Anaphylaxis: Facilities for managing allergic reactions must be available.
Adverse Events (Postmarketing)
Reported reactions include gout, arthritis, myalgia, fever, fatigue, rash, optic ischemic neuropathy, new-onset immune-mediated diseases, gastrointestinal distress, arthralgia, infective pneumonia, influenza, neuralgia, and rare fatalities.
AS01B Adjuvant and QS21 Concerns
The AS01B adjuvant, containing QS21, is linked to systemic reactions in up to 50% of recipients. QS21’s cytotoxicity can cause necrosis at the injection site and form pores in cell membranes, potentially leading to severe local and systemic effects.
Alternative Perspectives
Some advocate natural protocols for shingles, claiming they address root causes and clear the virus within 14 days, unlike antiviral treatments or vaccines, which critics argue may not resolve underlying issues.
Source Information
This summary draws from the SHINGRIX package insert and related studies, accessible via the FDA and PubMed. For natural treatment protocols, consult qualified healthcare providers.
